F2G Ltd. has raised a further $70 million in venture capital as it continues preparations to submit a new drug application to the U.S. FDA for its novel antifungal drug, olorofim, before the end of 2022.
Sironax Ltd. has raised $200 million in a series B financing round to support the development of its receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors. The latest financing has brought the capital raised by the Beijing and Shanghai-based company to more than $300 million to date.
Spintech MRI Inc. raised $6.5 million in series A financing to expand deployment of MRI software designed to improve and accelerate diagnosis and treatment of Parkinson’s disease, Alzheimer’s and other neurological diseases. The FDA-cleared Strategically Acquired Gradient Echo (Stage) platform is currently in use at more than 50 U.S. hospitals and institutions, including the Yale School of Medicine for advanced research, analysis and treatment of Parkinson’s disease.
In vitro diagnostics company Gaugene Biotechnology Ltd. has secured more than ¥100 million (US$14.8 million) in a series B financing to develop new products and technologies, as well as expand to new markets. The financing was led by Fortune Venture Capital Co. Ltd., with participation by Tao Capital, Guangdong Hybribio Biotech Co. Ltd., Qiming Venture Partners, and others.
RSS
